Fig. 6: Regulation of PD-L1 by the α-KG-TET2/3-p-STAT1/3 axis is required. | Cell Death & Disease

Fig. 6: Regulation of PD-L1 by the α-KG-TET2/3-p-STAT1/3 axis is required.

From: Supplementation with α-ketoglutarate improved the efficacy of anti-PD1 melanoma treatment through epigenetic modulation of PD-L1

Fig. 6: Regulation of PD-L1 by the α-KG-TET2/3-p-STAT1/3 axis is required.

A Designed primers for hMeDIP analysis and ChIP experiments. B 5-hmC levels of PD-L1 promoters in B16F10 tumor-bearing mouse tissues after the designated treatments. C, D ChIP-qPCR was performed to detect the binding of STAT1 C or STAT3 D to PD-L1 promoter sites in B16F10 cells with or without α-KG treatment. E Immunoprecipitation analysis of TET3 with p-STAT1/3 in B16F10 cells receiving the designated treatments. F P-STAT1/3 protein levels at different time points after IFNγ stimulation in B16F10 cells treated with CHX (100 mg/mL) or α-KG (200 μm). G The expression of p-STAT1/3 and PD-L1 protein levels was detected by immunoblotting after knocking down TET2 (left panel) /TET3 (right panel) under the designated treatment. H Schematic diagram of the mechanism. Multiple experimental data (n = 3) are counted and presented according to the statistical methods, and an asterisk (*) indicates the degree of significant difference.

Back to article page